Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate
For instance, the SELECT trial reported a 20% reduction in major adverse cardiovascular events among participants using Semaglutide compared to a placebo
While Ive been more consistent about reducing alcohol and caffeine, I still enjoy sweet foods and often use low- and non-nutritive sweeteners to satisfy cravings without completely derailing my health goals
For endurance athletes, raisins are a great alternative for expensive sports chews and gels
The intake is women-focused, fitting the audience for this drug
PubChem CID 92432, CAS 121062-08-6, MW 1024.2 g/mol
